Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicentre, Randomized, Prospective, Open-label Trial of Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318 is registered in ClinicalTrials.gov with German CLL Study Group as lead sponsor.

NCT NCT04608318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04608318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicentre, Randomized, Prospective, Open-label Trial of Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Lead sponsor
German CLL Study Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 1, 2021
Completion date
September 30, 2027
Enrollment
897 (estimated)
Sites
181

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphoid leukemia